RNA interference in the brain inhibits neurodegeneration in a polyglutamine disease, SCA1. Is this now the way forward for the clinical treatment of certain genetic disorders (pages 816–820)?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Renee Lucas
References
Elbashir, S.M. et al. Nature 411, 494–498 (2001).
Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Proc. Natl. Acad. Sci. USA 98, 9742–9747 (2001).
Xia, H. et al. Nat. Med. 8, 816–820 (2004).
Schols, L., Bauer, P., Schmidt, T., Schulte, T. & Riess, O. Lancet Neurol 3, 291–304 (2004).
Taylor, J.P., Hardy, J. & Fischbeck, K.H. Science 296, 1991–1995 (2002).
Paulson, H. Nat. Med. 9, 825–826 (2003).
Caplen, N.J. Gene Ther. 11, in the press (2004).
Dykxhoorn, D.M., Novina, C.D. & Sharp, P.A. Nat. Rev. Mol. Cell. Biol. 4, 457–467 (2003).
Flotte, T. Gene Ther. 11, 805–810 (2004).
Howard, K. Nat. Biotechnol. 21, 1117–1118 (2003).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Caplen, N. RNAi quashes polyQ. Nat Med 10, 775–776 (2004). https://doi.org/10.1038/nm0804-775
Issue Date:
DOI: https://doi.org/10.1038/nm0804-775
